In agreement with this study, Meyo et al. reported that NSCLC patients with high baseline levels of sPD-1 and sPD-L1 rendered shorter PFS and OS after treatment with nivolumab [27]. Here, SPDL1 is linked to non-small cell lung carcinoma.